Documents

Biperiden(C)

Description
Drug Study
Categories
Published
of 2
All materials on our website are shared by users. If you have any questions about copyright issues, please report us to resolve them. We are always happy to assist you.
Related Documents
Share
Transcript
   DRUG   STUDY   GENERIC   NAME: Biperiden Brand   name:  Akineton  Drug   Classification:  Anticholinergic  DOSAGE,   ROUTE,   FREQUENCY   (prescribed   and   recommended) INDICATION MECHANISM   OF   ACTION SIDE   EFFECTS   and   ADVERSE   REACTIONS   (by   system)    Parkinsonism: 2 mg PO TID to QID; individualize dosage. Maximum, 16 mg/day (8 tablets).    Drug-induced Extrapyramidal Disorders: 2 mg PO daily to TID    Adjunct in therapy of parkinsonism.    Relief of symptoms of extrapyramidal disorders that accompany phenothiazine therapy   Anticholinergic activity in the CNS that is believed to help normalize the hypothesized imbalance of cholinergic and dopaminergic neurotransmission in the basal ganglia in the brain of a parkinsonism patient.   CNS: Disorientation CV: Orthostatic hypotension Dermatologic: Rash EENT: Blurred vision GU: Urinary retention CONTRAINDICATION/S NURSING   RESPONSIBILITIES   (at   least   10)    Hypersensitivity to Benztropine    Angle-closure Glaucoma    Pyloric or Duodenal Obstruction    Peptic Ulcer    Myasthenia Gravis 1.   Give with caution, and reduce dosage in hot weather. 2.   Give with meals if GI upset occurs. 3.   Ensure that patient voids just before receiving each dose of drug if urinary retention is a problem. 4.   Drug interferes with sweating and ability of body to maintain heat equilibrium. 5.   Decrease dosage or discontinue temporarily if dry mouth makes swallowing or speaking difficult. Patient’s N ame / Room No.   

NASA SR 71

Mar 12, 2018
We Need Your Support
Thank you for visiting our website and your interest in our free products and services. We are nonprofit website to share and download documents. To the running of this website, we need your help to support us.

Thanks to everyone for your continued support.

No, Thanks